Who Paid My Doc
Emily Riser
Birmingham, AL Medical Doctor
NPI 1124115068 CMS profile 1310558
509 Brookwood Blvd, Suite 101, Birmingham, AL 35209
General payments
$231,356
Research payments
$1,477
Ownership & investment interest
$0
Research they led as principal investigator
$6,866,093
Through program year 2025, Emily Riser of Birmingham, AL is reported in the CMS Open Payments database as having received $231,356 across 1,055 general payments and $1,477 in research payments paid to them. Separately, studies naming them as principal investigator received $6,866,093 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $22,117 | 193 | |
| 2024 | General | $33,045 | 194 | |
| 2024 | Research | $1,081 | 1 | |
| 2023 | General | $15,500 | 174 | |
| 2023 | Research | $396 | 1 | |
| 2022 | General | $11,191 | 105 | |
| 2021 | General | $6,132 | 88 | |
| 2020 | General | $36,147 | 77 | |
| 2019 | General | $107,224 | 224 |
Beside peers
- Emily Riser
- Alabama median
- Middle half of Alabama
- National median
In program year 2025, general payments to Emily Riser were reported at $22,117. Among 16,848 Alabama profiles paid that year, the median was $180 and the middle half received between $51 and $664.
Show as a table
| Year | Emily Riser | Alabama median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $107,224 | $198 | $62–$700 | $163 |
| 2020 | $36,147 | $137 | $41–$482 | $114 |
| 2021 | $6,132 | $151 | $42–$552 | $132 |
| 2022 | $11,191 | $167 | $49–$619 | $149 |
| 2023 | $15,500 | $174 | $48–$631 | $160 |
| 2024 | $33,045 | $168 | $49–$626 | $164 |
| 2025 | $22,117 | $180 | $51–$664 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 108 drugsPart D claims
7,028
Drug cost
$5,290,486
Branded share of claims
28.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Soliris Eculizumab | Brand | 30 | $1,595,642 | |
| Kesimpta Pen Ofatumumab | Brand | 74 | $682,697 | |
| Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 | Brand | 114 | $483,139 | |
| Aubagio Teriflunomide | Brand | 39 | $348,551 | |
| Gamunex-C Immune Globul G/Gly/Iga Avg 46 | Brand | 29 | $314,446 | |
| Copaxone Glatiramer Acetate | Brand | 49 | $296,771 | |
| Tysabri Natalizumab | Brand | 25 | $204,495 | |
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | Brand | 17 | $149,814 | |
| Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 | Brand | 17 | $145,024 | |
| Panzyga Immun Glob G(Igg)-Ifas/Glycine | Brand | 12 | $119,672 |
The 10 drugs with the highest cost, of 108 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 28 billing codesPaid by Medicare
$942,505
Medicare patients
215
Services billed
34,968
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 64% | |
| Arthritis | 47% | |
| Depression | 34% | |
| Diabetes | 24% | |
| Ischemic heart disease | 16% | |
| Osteoporosis | 16% | |
| Chronic kidney disease | 15% | |
| COPD | 13% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, ocrelizumab, 1 mg J2350 | Office | 15 | 13,200 | $519,512 |
| Injection, methylprednisolone sodium succinate, 5 mg J2919 | Office | 26 | 8,049 | $1,824 |
| Injection, methylprednisolone sodium succinate, up to 125 mg J2930 | Office | 14 | 124 | $438 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 36 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| BRIUMVI |
|
$9,441 | — | — |
| SOLIRIS |
|
$5,515 | 30 | — |
| Mavenclad |
|
$3,450 | — | — |
| INGREZZA |
|
$457 | — | — |
| Rystiggo |
|
$261 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 36 with PatronRecords
1,057 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.